JP7358337B2 - レシニフェラトキシンの製剤 - Google Patents

レシニフェラトキシンの製剤 Download PDF

Info

Publication number
JP7358337B2
JP7358337B2 JP2020514270A JP2020514270A JP7358337B2 JP 7358337 B2 JP7358337 B2 JP 7358337B2 JP 2020514270 A JP2020514270 A JP 2020514270A JP 2020514270 A JP2020514270 A JP 2020514270A JP 7358337 B2 JP7358337 B2 JP 7358337B2
Authority
JP
Japan
Prior art keywords
rtx
formulation
alcoholic
formulations
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020514270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533336A5 (cg-RX-API-DMAC7.html
JP2020533336A (ja
Inventor
ブライアン ジョーンズ,
アレクシス ナハマ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of JP2020533336A publication Critical patent/JP2020533336A/ja
Publication of JP2020533336A5 publication Critical patent/JP2020533336A5/ja
Priority to JP2022162509A priority Critical patent/JP2022176377A/ja
Application granted granted Critical
Publication of JP7358337B2 publication Critical patent/JP7358337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020514270A 2017-09-11 2018-09-11 レシニフェラトキシンの製剤 Active JP7358337B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022162509A JP2022176377A (ja) 2017-09-11 2022-10-07 レシニフェラトキシンの製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556824P 2017-09-11 2017-09-11
US62/556,824 2017-09-11
PCT/IB2018/056944 WO2019049112A1 (en) 2017-09-11 2018-09-11 RESINIFERATOXIN FORMULATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162509A Division JP2022176377A (ja) 2017-09-11 2022-10-07 レシニフェラトキシンの製剤

Publications (3)

Publication Number Publication Date
JP2020533336A JP2020533336A (ja) 2020-11-19
JP2020533336A5 JP2020533336A5 (cg-RX-API-DMAC7.html) 2021-10-21
JP7358337B2 true JP7358337B2 (ja) 2023-10-10

Family

ID=63708422

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020514270A Active JP7358337B2 (ja) 2017-09-11 2018-09-11 レシニフェラトキシンの製剤
JP2022162509A Pending JP2022176377A (ja) 2017-09-11 2022-10-07 レシニフェラトキシンの製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022162509A Pending JP2022176377A (ja) 2017-09-11 2022-10-07 レシニフェラトキシンの製剤

Country Status (9)

Country Link
US (3) US20190076396A1 (cg-RX-API-DMAC7.html)
EP (1) EP3681472A1 (cg-RX-API-DMAC7.html)
JP (2) JP7358337B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200051771A (cg-RX-API-DMAC7.html)
CN (1) CN111315360B (cg-RX-API-DMAC7.html)
AU (1) AU2018327301B2 (cg-RX-API-DMAC7.html)
CA (1) CA3074951A1 (cg-RX-API-DMAC7.html)
MX (2) MX2020002692A (cg-RX-API-DMAC7.html)
WO (1) WO2019049112A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2020226370A1 (ko) 2019-05-09 2020-11-12 주식회사 엘지화학 전기화학소자용 분리막 및 이를 포함하는 전기화학소자
US20230143545A1 (en) * 2020-03-30 2023-05-11 Board Of Regents Of The University Of Nebraska Treating Pulmonary Inflammatory Disease Associated With Covid-19 By Administering Resiniferatoxin
ES3004508T3 (en) * 2020-04-15 2025-03-12 Gruenenthal Gmbh Resiniferatoxin compositions
WO2021257956A1 (en) * 2020-06-19 2021-12-23 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of bladder pain or bladder cancer
EP4291174A1 (en) * 2021-02-11 2023-12-20 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of prostate cancer
US20250228765A1 (en) 2024-01-15 2025-07-17 Gruenenthal Gmbh Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525505A (ja) 2004-12-28 2008-07-17 メステックス アクチェンゲゼルシャフト バニロイド受容体アゴニストをグリコースアミノグリカンまたはプロテオグリカンとともに関節痛治療のための薬剤の製造に用いることおよび前記薬剤の適用方法
JP2008525504A (ja) 2004-12-28 2008-07-17 メステックス アクチェンゲゼルシャフト 関節痛を治療する薬剤を生成するためのレシニフェラトキシン(rtx)の使用方法および前記薬剤を適用する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
NZ540769A (en) * 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CN113490745A (zh) * 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
WO2020154261A1 (en) * 2019-01-22 2020-07-30 Sorrento Therapeutics, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525505A (ja) 2004-12-28 2008-07-17 メステックス アクチェンゲゼルシャフト バニロイド受容体アゴニストをグリコースアミノグリカンまたはプロテオグリカンとともに関節痛治療のための薬剤の製造に用いることおよび前記薬剤の適用方法
JP2008525504A (ja) 2004-12-28 2008-07-17 メステックス アクチェンゲゼルシャフト 関節痛を治療する薬剤を生成するためのレシニフェラトキシン(rtx)の使用方法および前記薬剤を適用する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GABRIEL C TENDER; ET AL,SELECTIVE ABLATION OF NOCICEPTIVE NEURONS FOR ELIMINATION OF HYPERALGESIA AND NEUROGENIC INFLAMMATION,NEUROSURGICAL FOCUS,2005年05月,VOL:18, NR:5,PAGE(S):1 - 5,http://dx.doi.org/10.3171/foc.2005.18.5.12
KARAI L; ET AL,DELETION OF VANILLOID RECEPTOR 1_EXPRESSING PRIMARY AFFERENT NEURONS FOR PAIN CONTROL,THE JOURNAL OF CLINICAL INVESTIGATION,英国,BMJ GROUP,2004年,VOL:113, NR:9,PAGE(S):1344 - 1352,http://dx.doi.org/10.1172/JCI20449

Also Published As

Publication number Publication date
KR20200051771A (ko) 2020-05-13
US20220370405A1 (en) 2022-11-24
AU2018327301A1 (en) 2020-04-09
AU2018327301B2 (en) 2024-08-22
CN111315360B (zh) 2025-01-17
CA3074951A1 (en) 2019-03-14
MX2020002692A (es) 2020-10-14
MX2022013947A (es) 2022-11-30
JP2020533336A (ja) 2020-11-19
EP3681472A1 (en) 2020-07-22
WO2019049112A1 (en) 2019-03-14
US20250000842A1 (en) 2025-01-02
JP2022176377A (ja) 2022-11-25
CN111315360A (zh) 2020-06-19
US20190076396A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
JP2022176377A (ja) レシニフェラトキシンの製剤
KR101593579B1 (ko) 치료용 조성물
CN101959501B (zh) 稳定的含多西紫杉醇的单液药用组合物
US11020485B2 (en) Pharmaceutical formulation
CN110251463A (zh) 含激素的乳液
JP2018515484A (ja) カバジタキセル脂肪乳剤注射剤、その調製方法およびその使用
ES2348920T3 (es) Agonistas de adrenoceptores beta-2 para el tratamiento de enfermedades del tejido conectivo de la piel.
US20180028489A1 (en) Stable cannabinoid formulations
KR20150114505A (ko) 불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형
Singh et al. Formulation development & evaluation of topical gel formulations using different gelling agents and its comparison with marketed gel formulation
US20140371242A1 (en) Azathioprine Oral Suspensions and Methods of Use
US20240033230A1 (en) Compositions for the treatment of blepharitis
US9504751B2 (en) Stable pharmaceutical composition
EP2429510B1 (en) Oil-in-water emulsion of mometasone and propylene glycol
JP2010132607A (ja) アトピー性皮膚炎治療用軟膏剤
ES2625112T3 (es) Loción en emulsión de tipo aceite en agua que contiene 22-oxa-1 alfa,25-dihidroxivitamina D3 y método de tratamiento de una enfermedad cutánea utilizando la misma
Vieillard et al. Physicochemical stability study of a new Trimix formulation for treatment of erectile dysfunction
JP2007224022A (ja) 22−オキサ−1α,25−ジヒドロキシビタミンD3を含有する水中油型乳剤性ローション剤
BR102021002197A2 (pt) Método de tratamento, uso e composição veterinária injetável tixotrópica para liberação controlada de doramectina e vitamina e
DE10234784A1 (de) Intravenös applizierbare, pharmazeutische Darreichungsform
CA3151567A1 (en) Nanoparticle pharmaceutical delivery system
EP3135284A1 (en) Stable pharmaceutical composition
HK1245653B (en) Injectable pharmaceutical composition comprising dexamethasone sodium phosphate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230927

R150 Certificate of patent or registration of utility model

Ref document number: 7358337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350